LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

Home・Aktien・Pulmatrix Inc

Pulmatrix Inc

Geschlossen

1.26 2.44

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.21

Max

1.29

Schlüsselkennzahlen
By Trading Economics
Einkommen	-51K -928K
EPS	-0.254
Angestellte	2
EBITDA	-51K -928K

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-6.6M 4.8M
Vorheriger Eröffnungskurs	-1.18
Vorheriger Schlusskurs	1.26

Pulmatrix Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

12. Mai 2026, 22:50 UTC

Ergebnisse

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

12. Mai 2026, 22:49 UTC

Ergebnisse

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

12. Mai 2026, 22:32 UTC

Ergebnisse

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

12. Mai 2026, 23:48 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

12. Mai 2026, 22:57 UTC

Market Talk

Ergebnisse

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

12. Mai 2026, 22:26 UTC

Ergebnisse

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

12. Mai 2026, 22:25 UTC

Ergebnisse

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

12. Mai 2026, 22:25 UTC

Ergebnisse

Aristocrat Leisure Interim Dividend A$0.50/Security

12. Mai 2026, 22:24 UTC

Ergebnisse

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

12. Mai 2026, 22:23 UTC

Ergebnisse

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

12. Mai 2026, 22:23 UTC

Ergebnisse

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

12. Mai 2026, 22:19 UTC

Ergebnisse

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

12. Mai 2026, 22:14 UTC

Ergebnisse

CBA: Business Lending Continued to Grow Above System>CBA.AU

12. Mai 2026, 22:14 UTC

Ergebnisse

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

12. Mai 2026, 22:13 UTC

Ergebnisse

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

12. Mai 2026, 22:12 UTC

Ergebnisse

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

12. Mai 2026, 22:12 UTC

Ergebnisse

CBA 3Q New Home Loan Funding A$45B>CBA.AU

12. Mai 2026, 22:11 UTC

Ergebnisse

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

12. Mai 2026, 22:11 UTC

Ergebnisse

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

12. Mai 2026, 22:10 UTC

Ergebnisse

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

12. Mai 2026, 22:09 UTC

Ergebnisse

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

12. Mai 2026, 22:09 UTC

Ergebnisse

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

12. Mai 2026, 22:08 UTC

Ergebnisse

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

12. Mai 2026, 22:07 UTC

Ergebnisse

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

12. Mai 2026, 22:06 UTC

Ergebnisse

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

12. Mai 2026, 22:06 UTC

Ergebnisse

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

12. Mai 2026, 22:05 UTC

Ergebnisse

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

12. Mai 2026, 22:04 UTC

Ergebnisse

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

12. Mai 2026, 22:04 UTC

Ergebnisse

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

12. Mai 2026, 22:04 UTC

Ergebnisse

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Peer-Vergleich

Kursveränderung

Pulmatrix Inc Prognose

Rating-Konsens

By TipRanks

0 ratings

Buy

Halten

Sell

Basierend auf 0 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Pulmatrix Inc – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Pulmatrix Inc

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.